Living with Alzheimer's Disease

Questions clinicians ask

How are blood-based biomarkers changing the diagnosis and early detection of Alzheimer's disease?

Blood-based biomarkers are emerging as tools for detecting the biological changes of Alzheimer's disease earlier and reducing reliance on prolonged clinical observation alone. The briefs describe their potential to reshape diagnostic pathways, while emphasizing that clinical interpretation remains central.

What role does amyloid beta play in Alzheimer's disease, and why does treatment timing matter?

Amyloid beta is a defining biological feature of Alzheimer's disease pathology and a major therapeutic target. The covered evidence indicates that anti-amyloid monoclonal antibodies such as lecanemab and donanemab are most relevant when initiated early in the disease course.

Which nonpharmacologic factors are associated with lower Alzheimer's disease or dementia risk?

The briefs report that speed-based cognitive training may reduce subsequent dementia risk, while adherence to the MIND diet is associated with slower structural brain atrophy. Weak or highly variable circadian rhythms are associated with greater dementia risk, although such associations do not establish that rhythm modification prevents Alzheimer's disease.

Are retinal biomarkers ready for routine Alzheimer's disease diagnosis?

Retinal markers are being studied as accessible indicators of early biological changes related to Alzheimer's disease. The coverage characterizes retinal diagnostics as an emerging approach rather than an established standalone diagnostic method.

Other conditions

• ADHD
• Allergy
• ALS
• Antimicrobial Resistance
• Anxiety
• Asthma
• Atopic Dermatitis
• Atrial Fibrillation
• Autism
• Breast Cancer
• Cervical Cancer
• Chronic Kidney Disease